Primary biliary cholangitis (PBC), a rare, chronic liver disease, impacts 58 out of every 100,000 women and 15 out of every 100,000 men in the United States. With no known cause and no known cure, many patients must be treated with a combination of symptom management and potentially ineffective liver medications — but even this can result in debilitating symptoms as the disease progresses.
This means there is a clear necessity to research better treatment options for PBC patients. In this whitepaper, we thoroughly analyze the demographics of PBC patients from the Antidote database and put that information into a context that can help sponsors determine study design and recruitment plans that can set trials up for success. Use the form to get your copy today.
Use the form to get your copy today.
